TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05346419
Drug: Risedronate
Normalized name: Risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants received risedronate 35 mg once a week for 6 months.
Study: NCT05346419
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received 2,800 IU of vitamin D once a week, with additional daily supplementation of 4,000 IU of vitamin D
Study: NCT05541107
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous Amphotericin B
Study: NCT05548270
Drug: DPI-386 Nasal Gel
Normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects will self-administer DPI-386 Nasal Gel or Placebo
Study: NCT06437522
Drug: BL-B01D1
Normalized name: BL-1020
DrugBank: BL-1020 (DB05687)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration by intravenous infusion for a cycle of 3 weeks.
Study: NCT06437522
Drug: PD-1 monoclonal antibody
Normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration by intravenous infusion for a cycle of 3 weeks.
Study: NCT05263778
Drug: Bempedoic Acid / Ezetimibe Oral Tablet
Normalized name: bempedoic acid / ezetimibe Oral Tablet
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bempedoic acid 180 mg/ezetimibe 10 mg by mouth once daily for 12 weeks
Study: NCT06772857
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin is a drug used to manage blood glucose levels. It improves insulin sensitivity and reduces glucose production in the liver. This regimen will be provided to all study groups (A, B, and C) in combination with the respective interventions described for each group. Participants are instructed not to change their physical activity during the study.
Study: NCT05316376
Drug: albumin-bound paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: albumin-bound paclitaxel (100 mg/m2, days 1, 8, and 15, every 4 weeks) combined with carboplatin (AUC = 5 day 1, every 4 weeks)
Study: NCT05316376
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: paclitaxel (175 mg/m2, day 1, every 3 weeks) combined with carboplatin (AUC=6, day1, every 3 weeks)
Study: NCT04865536
Drug: 1800 mg TBI-223
Normalized name: TBI-223
DrugBank: TBI-223 (DB18911)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 x 600 mg SR1 tablets
Study: NCT04865536
Drug: 2400mg TBI-223
Normalized name: TBI-223
DrugBank: TBI-223 (DB18911)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 x 600 mg SR1 tablets and 1 x 600 mg IR tablets
Study: NCT04865536
Drug: 3000mg TBI-223
Normalized name: TBI-223
DrugBank: TBI-223 (DB18911)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 x 600 mg SR1 tablets and 1 x 600 mg IR tablets
Study: NCT04865536
Drug: TBI-223 Placebo
Normalized name: TBI-223
DrugBank: TBI-223 (DB18911)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 x Placebo tablets
Study: NCT05559541
Drug: AK119
Normalized name: AK119
DrugBank: AK119 (DB16423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AK119 is an anti-CD73 monoclonal antibody.
Study: NCT04865536
Drug: TBI-223 Placebo
Normalized name: TBI-223
DrugBank: TBI-223 (DB18911)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 x Placebo tablets
Study: NCT04865536
Drug: TBI-223 Placebo
Normalized name: TBI-223
DrugBank: TBI-223 (DB18911)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 x Placebo tablets
Study: NCT05559541
Drug: AK104
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: AK104 is an anti-PD-1 and CTLA-4 bispecific antibody.
Study: NCT06363552
Drug: SC0191 + Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1. The SC0191 tablet is taken orally at a dose of 300mg once daily. Each treatment cycle consists of 28 days. Medication is administered on days 1 to 3, days 8 to 10, days 15 to 17, and days 22 to 24 of each cycle.~2. Bevacizumab injection is administered intravenously at a dose of 5mg/kg on day 1 and day 15 of each treatment cycle.
Study: NCT06470334
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultrasound-guided PENG block - 20ml 0,2% ropivacaine
Study: NCT06470334
Drug: Ropivacaine+Dexamethasone
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultrasound-guided PENG block - 10ml 0,2% ropivacaine + 4mg Dexamethasone
Study: NCT00089869
Drug: olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00089869
Drug: atomoxetine
Normalized name: Atomoxetine
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04600323
Drug: Sodium Bicarbonate Tablets
Normalized name: Sodium Bicarbonate Tablets
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be given sodium bicarbonate at 0.5 mEq/kg-LBW/day for 12 months
Study: NCT04883775
Drug: MVT-2163
Normalized name: magnesium oxide
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MVT-2163 is administered intravenously as a PET imaging agent.
Study: NCT04883775
Drug: MVT-5873
Normalized name: magnesium oxide
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MVT-5873 will be administered intravenously over at least 60 minutes.
Study: NCT06351332
Drug: Azenosertib
Normalized name: Azenosertib
DrugBank: Azenosertib (DB18028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: WEE1 inhibitor, 25 or 100 mg tablet, taken orally per protocol.
Study: NCT06351332
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Platinum coordination compound, 5-, 15-, 45-, and 60-mL vials, via intravenous (into the vein) infusion per institutional standards.
Study: NCT06351332
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Humanized immunoglobulin G4 monoclonal antibody, 4-mL vials, via intravenous (into the vein) infusion per protocol.
Study: NCT00474591
Drug: Fondaparinux
Normalized name: Fondaparinux
DrugBank: Fondaparinux (DB00569)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05440383
Drug: Leuprorelin
Normalized name: Leuprorelin
DrugBank: Leuprolide (DB00007)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous administration
Study: NCT05767229
Drug: Carvedilol
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carvedilol 0.2 mg/kg for 1.5 hrs
Study: NCT04970901
Drug: Loncastuximab Tesirine
Normalized name: Loncastuximab tesirine
DrugBank: Loncastuximab tesirine (DB16222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous (IV) infusion
Study: NCT04970901
Drug: Polatuzumab Vedotin
Normalized name: polatuzumab vedotin
DrugBank: Polatuzumab vedotin (DB12240)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV infusion
Study: NCT04970901
Drug: Glofitamab
Normalized name: Glofitamab
DrugBank: Glofitamab (DB16371)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT04970901
Drug: Mosunetuzumab
Normalized name: Mosunetuzumab
DrugBank: Mosunetuzumab (DB15434)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) injection
Study: NCT04970901
Drug: Obinutuzumab
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV infusion
Study: NCT05785442
Drug: Anakinra Prefilled Syringe
Normalized name: anakinra Prefilled Syringe
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Anakinra 100 mg administration subcutaneously once daily for 10 days (at least 4 days)
Study: NCT05402345
Drug: GlcNAc-GlcN
Normalized name: D-GlcNAc
DrugBank: N-Acetylglucosamine (DB00141)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GlcNAc powder - weight-dependent dose
Study: NCT04762888
Drug: Gallium Ga 68 Gozetotide
Normalized name: LOCAMETZ Kit for the Preparation of Gallium Ga 68 Gozetotide Injection
DrugBank: Gallium nitrate (DB05260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00000856
Drug: Foscarnet sodium
Normalized name: Foscarnet Sodium
DrugBank: Foscarnet (DB00529)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00000856
Drug: Ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05273671
Drug: Nalbuphine
Normalized name: Nalbuphine
DrugBank: Nalbuphine (DB00844)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: will receive 0.1 mg/kg NAL diluted in 10 ml I.V 10 minutes before the end of surgery
Study: NCT05273671
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: will receive dexmedetomedine 0.5 mic/kg diluted in 10 ml I.V 10 minutes before the end of surgery
Study: NCT05583604
Drug: secukinumab
Normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The recommended dose is 300 mg of secukinumab by subcutaneous injection with initial dosing at weeks 0, 1, 2, 3 and 4, followed by a maintenance dose of 300 mg every 2 weeks. Each 300 mg dose is given as one subcutaneous injection of 300 mg or as two subcutaneous injections of 150 mg.
Study: NCT04936126
Drug: Quetiapine
Normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quetiapine XR 100 mg/day augmentation to the ongoing Sertraline treatment for the study period
Study: NCT04936126
Drug: Amantadine
Normalized name: Amantadine
DrugBank: Amantadine (DB00915)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amantadine 200 mg/day (in two divided doses) augmentation to the ongoing Sertraline treatment for the study period
Study: NCT04936126
Drug: Pramipexole
Normalized name: Pramipexole
DrugBank: Pramipexole (DB00413)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pramipexole 0.375 mg/day (in three divided doses) augmentation to the ongoing Sertraline treatment for the study period
Study: NCT05959356
Drug: Cetuximab + Envafolimab + mFOLFOXIRI
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab 500mg/m² + envafolimab 200mg + irinotecan 150 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2400 mg/m² civ. 46h all on day 1 of each 2 weeks cycle up to max 8 cycles, followed by maintenance with cetuximab 500mg/m² + envafolimab 200mg + leucovorin 200 mg/m² + 5-FU 2400 mg/m² civ. 46h all on day 1 of each 2 weeks cycle until PD, unacceptable toxicity or patient's refusal.
Study: NCT05959356
Drug: Cetuximab + mFOLFOX6/FOLFIRI
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab 500mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2400 mg/m² civ. 46h or cetuximab 500mg/m² + irinotecan 180 mg/m² + leucovorin 200 mg/m² + 5-FU 2400 mg/m² civ. 46h all on day 1 of each 2 weeks cycle up to max 8 cycles, followed by maintenance with cetuximab 500mg/m² + leucovorin 200 mg/m² + 5-FU 2400 mg/m² civ. 46h all on day 1 of each 2 weeks cycle until PD, unacceptable toxicity or patient's refusal.
Study: NCT05838118
Drug: Fecal Microbiota Transplantation
DrugBank: Fecal microbiota (DB17743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biologically active human fecal fluid (donor stool) is provided in fluid form.
Study: NCT06032845
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: a PD-1 immune check inhibitor
Study: NCT06032845
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenvatinib capsules
Study: NCT06035497
Drug: BMS-986369
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Specified dose on specified days
Study: NCT06722950
Drug: AC591
Normalized name: Acetaminophen and Codeine Phosphate
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AC591 : 3 times a day (daily), taken with boiled water.
Study: NCT05793268
Drug: Entecavir or Tenofovir
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of either entecavir or tenofovir treatment for 3 years
Study: NCT06722963
Drug: Nalbuphine
Normalized name: Nalbuphine
DrugBank: Nalbuphine (DB00844)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nalbuphine in doses ranging from 10 mg have been studied as adjuvants to bupivacaine
Study: NCT06723964
Drug: AP505
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: AP505 is a Anti-PD-L1 and Anti-VEGF Antibody Fusion Protein.
Study: NCT06724549
Drug: BN104
Normalized name: BN104
DrugBank: BN104 (DB18172)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This study adopts two-treatment (fasting or following a high-fat meal), two-period, two-sequence crossover design. The subjects will be randomly assigned into one of two treatment sequences in a 1:1 ratio. A single 600 mg dose of BN104 tablets administered under fasting conditions or after a standard high-fat breakfast in period 1 and 2.
Study: NCT06441916
Drug: Dabigatran Etexilate Capsules 150 mg
Normalized name: dabigatran etexilate 150 MG
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dabigatran Etexilate
Study: NCT05113069
Drug: SHR-A1912
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-A1912, dose escalation and expansion.
Study: NCT05147090
Drug: Empagliflozin 10 MG
Normalized name: empagliflozin 10 MG
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Empagliflozin 10mg daily
Study: NCT05965544
Drug: Bupivacain (preoperative)
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After the patients are in the supine position and aseptic conditions are provided in the preoperative period, the fascia on the iliacus muscle will be determined with the help of an 8-12 MHz linear probe and a block will be applied with the in-plane technique. During the block, 0.2% bupivacaine concentration 0.5 mL/kg is routinely used in patients.
Study: NCT05965544
Drug: Bupivacaine-fentanyl
Normalized name: Bupivacaine-Fentanyl
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patient will be placed in the lateral decubitus position with the fractured side up. After the spinal anesthesia method was provided with aseptic conditions, 10 mg 0.5% bupivacaine + 20 mcg Fentanyl injection will be applied using a 26 Gauge pencil point needle through the L3-L4 or L4-L5 intervertebral space
Study: NCT05965544
Drug: Bupivacain (Postoperative)
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After the patients are in the supine position and aseptic conditions are provided in the postoperative period, the fascia on the iliacus muscle will be determined with the help of an 8-12 MHz linear probe and a block will be applied with the in-plane technique. During the block, 0.2% bupivacaine concentration 0.5 mL/kg is routinely used in patients.
Study: NCT05912192
Drug: Elonide Nasal Spray
Normalized name: Desonide
DrugBank: Desonide (DB01260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50mcg/dose One puff for each nostrils twice daily
Study: NCT05912192
Drug: Nasonex Nasal Spray
Normalized name: mometasone Metered Dose Nasal Spray [Nasonex]
DrugBank: Mometasone (DB00764)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50mcg/dose One puff for each nostrils twice daily
Study: NCT06371040
Drug: CD19-BCMA Targeted CAR-T Dose 1
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0 e5/ kg CD19-BCMA CAR-T positive T cells
Study: NCT06371040
Drug: CD19-BCMA Targeted CAR-T Dose 2
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 e6/ kg CD19-BCMA CAR-T positive T cells
Study: NCT06371040
Drug: CD19-BCMA Targeted CAR-T Dose 2
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 e6/ kg CD19-BCMA CAR-T positive T cells
Study: NCT04667052
Drug: JNJ 64304500
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single subcutaneous dose of JNJ-64304500 reference formulation.
Study: NCT04667052
Drug: JNJ 64304500
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single subcutaneous dose of JNJ-64304500 test formulation.
Study: NCT00000172
Drug: Galantamine
Normalized name: Galantamine
DrugBank: Galantamine (DB00674)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04612712
Drug: Donafenib Tosilate Tablets
Normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In the dose exploration phase (phase I) : three doses of Donafenib tosylate tablets \[50 mg twice a day; 100 mg twice a day; 200 mg twice a day \] will be explored. In the dose expansion phase (phase II), patients with advanced hepatocellular carcinoma will be treated at the recommended dose for phase 2(RP2D).The RP2D will be determined by the dose escalation study.
Study: NCT05753696
Drug: Azilsartan
Normalized name: Azilsartan
DrugBank: Azilsartan medoxomil (DB08822)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azilsartan initial dose 20mg/d, if not reached the goal of hypertension; azilsartan dose 40mg/d
Study: NCT05753696
Drug: Losartan
Normalized name: Losartan
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: losartan initial dose 40mg/d, if not reached the goal of hypertension; losartan 100mg/d
Study: NCT00246675
Drug: Frusemide
Normalized name: Frusemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04888507
Drug: Pozelimab
Normalized name: Pozelimab
DrugBank: Pozelimab (DB15218)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) loading dose (once) followed after 30 minutes by sub-cutaneous (SC) administration
Study: NCT05302726
Drug: Estrogen
Normalized name: Estrogen
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal and oral estrogen both as substitution therapy
Study: NCT04888507
Drug: Cemdisiran
Normalized name: Cemdisiran
DrugBank: Cemdisiran (DB16121)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC administration
Study: NCT05649709
Drug: L-VA dual therapy
Normalized name: Tums Dual Action
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1000mg amoxicillin capsules twice times daily and 20mg vonoprazan Fumarate Tablets twice daily for 14 days
Study: NCT05649709
Drug: H-VA dual therapy
Normalized name: Tums Dual Action
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1000mg amoxicillin capsules three times daily and 20mg vonoprazan Fumarate Tablets twice daily for 14 days
Study: NCT04856488
Drug: Iodine-Potassium Iodide 5%-10% Oral and Topical Solution
Normalized name: iodine-potassium iodide 5%-10% oral and topical solution
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iodine Potassium Iodide 5% oral solution, administered 3 times per day for 10 days
Study: NCT04657861
Drug: APRIL CAR-T cells
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject receive APRIL CAR T-cells by intravenous infusion
Study: NCT06266832
Drug: Adebrelimab
Normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This product is administered by intravenously guttae. The recommended dose of subcutaneous injection is 20mg/kg, administered every 3 Weeks (Q3W).
Study: NCT06266832
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 130mg/m2, ivgtt, d1, Q3W
Study: NCT04355039
Drug: Pomalidomide
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4 mg Days 1-21
Study: NCT04355039
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 40 mg Days 1, 8, 15 and 22
Study: NCT04355039
Drug: INCB053914 50 mg bis in die (BID)
Normalized name: bis-hydroxyethoxypropyl dimethicone (50 CST)
DrugBank: Propyl acetate (DB01670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose level 0: 50 mg BID
Study: NCT04355039
Drug: INCB053914 65 mg BID
Normalized name: INCB053914
DrugBank: Uzansertib (DB17571)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose level 1: 65 mg BID
Study: NCT04355039
Drug: INCB053914 80 mg BID
Normalized name: INCB053914
DrugBank: Uzansertib (DB17571)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose level 2: 80 mg BID
Study: NCT04772612
Drug: sitravatinib
Normalized name: Sitravatinib
DrugBank: Sitravatinib (DB15036)
Approvals — FDA: no, EMA: no, PMDA: no
Description: sitravatinib
Study: NCT04950621
Drug: remimazolam
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Remimazolam will be administered during induction and maintenance for general anesthesia.
Study: NCT04950621
Drug: propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol will be administered during induction and maintenance for general anesthesia.
Study: NCT04660565
Drug: Prednisone and Belimumab
Normalized name: Belimumab
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Prednisone/prednisolone: started at 0.6-0. 8mg/kg.d for 2 to 4 weeks, tapered at 5mg per 1-2 weeks to equal to or less than 5mg per day in 3 months. Belimumab will start at the same time as the prednisone induction.
Study: NCT04660565
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone/prednisolone: started at 0.6-0. 8mg/kg.d for 2 to 4 weeks, tapered at 5mg per 1-2 weeks to equal to or less than 5mg per day in 3 months.